Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Dr. Jean-Pierre Bizzari
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(902)
•••
Comment by canadafanon Dec 15, 2023 11:17am
154 Views
Post# 35786716

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre BizzariRe azz34
I also support your well thought out post.
Many enjoy focusing on only negatives. Yes there are many,
However as you said, they have been able to get this far.
said many many times. Next few months will be interesting.
Now with change of both executive & a new science advisor, could become yet again a new starting point.
Built on top of the in place realrptionships & results with. Roche,
Weeks? Months?
Quite frankly with out a complete corporate/ financial reorganization, they don't have much past March.
partership? Buyout? Take the company private?
Another large scale bought deal?
imho The best thing Onc could do right now. Higher an outside advisor & publicly put the company up for sale.
I have seen it done with other companies.
works out well.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities